PU

Pulmocide

7 known investors

pulmocide.com ↗

Pulmocide develops inhaled medicines for difficult-to-treat respiratory diseases, with a lead compound (opelconazole) in Phase 3 trials for invasive pulmonary aspergillosis and other Aspergillus-associated conditions. The company focuses on patients not responding adequately to standard antifungal therapies.

Founders & leadership

DM

David Mantusin

Investors · 7

AD

Adjuvant CapitalNew York · $10M – $25M

F-

F-Prime Capital PartnersCambridge · $3M – $10M

JE

Jeito CapitalParis

LO

Longwood FundBoston

SR

SR One Capital ManagementRedwood City

SV

SV Health InvestorsBoston · $1M – $20M

VI

Vivo CapitalPalo Alto · $10M – $50M

In the news

Pulmocide Raises $52 Million to Fund Additional Late-Stage Development of Opelconazole - BioSpacebiospace.com · Dec 2022Pulmocide Raises $52 Million to Fund Additional Late-Stage Development of Opelconazole | Pulmocidepulmocide.com · Dec 2022Pulmocide Receives Investment from the Cystic Fibrosis Foundationfinance.yahoo.com · Dec 2021Pulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945globenewswire.com · May 2021London-based biotech company Pulmocide raises $30.4m Series Buktech.news · Mar 2017Pulmocide Limited: Pulmocide Raises $30 Million in Series B Financingglobenewswire.com · Mar 2017